Activation of Platelet mTORC2/Akt Pathway by Anti-β2GP1 Antibody Promotes Thrombosis in Antiphospholipid Syndrome
Arteriosclerosis, Thrombosis, and Vascular Biology · 2023-10 · 43 (10) · 1818-1832
DOI: 10.1161/atvbaha.123.318978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023-10. Verfasst von Zihan Tang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Ruijin Hospital (Z.T., H.S., J.T., H.L., Q.H., X.C., J.Y., Y. Su, Y. Sun, H.P., C.Y., T.L.), Shanghai Jiao…. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Anti-β2GP1 (β2-glycoprotein 1) antibodies are the primary pathogenic antibody to promote thrombosis in antiphospholipid syndrome (APS), yet the underlying mechanism remains obscure. We aimed to explore the intracellular pathway that mediated platelet activation. METHODS: Platelets were isolated from patients with APS and subjected to RNA sequencing. Platelet aggregation, the release of platelet granules, platelet spreading, and clot retraction were detected to evaluate platelet activation. We purified anti-β2GP1 antibodies from patients with APS and the total IgG from healthy donors to stimulate platelets with/without FcγRIIA (Fcγ receptor IIA) blocking antibody or Akt (protein kinase B) inhibitor. Platelet-specific Sin1 (stress-activated protein kinase–interacting protein) deficiency mice were established. The thrombus model of inferior vena cava flow restriction, ferric chloride–induced carotid injury model, and laser-induced vessel wall injury in cremaster arterioles model were constructed after administration of anti-β2GP1 antibodies. RESULTS: Combined RNA sequencing and bioinformatics analysis suggested that APS platelets exhibited increased levels of mRNA associated with platelet activation, which was in line with the hyperactivation of APS platelets in response to stimuli. Platelet activation in APS platelets was accompanied by upregulation of the mTORC2 (mammalian target of the rapamycin complex 2)/Akt pathway and increased levels of SIN1 phosphorylation at threonine 86. Anti-β2GP1 antibody derived from patients with APS enhanced platelet activation and upregulated the mTORC2/Akt pathway. Moreover, the Akt inhibitor weakened the potentiating effect of the anti-β2GP1 antibody on platelet activation. Notably, Sin1 deficiency suppresses anti-β2GP1 antibody–enhanced platelet activation in vitro and thrombosis in all 3 models. CONCLUSIONS: This study elucidated the novel mechanism involving the mTORC2/Akt pathway, which mediates the promotion of platelet activation and induction of thrombosis by the anti-β2GP1 antibody. The findings suggest that SIN1 may be a promising therapeutic target for the treatment of APS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Ruijin Hospital (Z.T., H.S., J.T., H.L., Q.H., X.C., J.Y., Y. Su, Y. Sun, H.P., C.Y., T.L.), Shanghai Jiao Tong University School of Medicine, China.
- Department of Laboratory Medicine, Ruijin Hospital (C.C., J.D., X.W.), Shanghai Jiao Tong University School of Medicine, China.
- Department of Immunology and Microbiology, Shanghai Institute of Immunology, Ministry of Education Key Laboratory of Cell Death and Differentiation (X.O., B.S.), Shanghai Jiao Tong University School of Medicine, China.
- Department of Tumor Biology, Shanghai Chest Hospital (X.O.), Shanghai Jiao Tong University School of Medicine, China.
- Department of Biochemistry and Molecular Cell Biology (J.L., Y.X.), Shanghai Jiao Tong University School of Medicine, China.
- Center for Human Translational Immunology at Shanghai Institute of Immunology, Ruijin Hospital (B.S.), Shanghai Jiao Tong University School of Medicine, China.
ORCID-Profile: Zihan Tang, Hui Shi, Changming Chen, Jialin Teng, Jing Dai, Honglei Liu, Qiongyi Hu, Xiaobing Cheng, Junna Ye, Yutong Su, Yue Sun, Haoyu Pan, Junling Liu, Bing Su, Chengde Yang, Yanyan Xu, Tingting Liu
Zitieren
APA
Tang, Z., Shi, H., Chen, C., Teng, J., Dai, J., Ouyang, X., Liu, H., Hu, Q., Cheng, X., Ye, J., Su, Y., Sun, Y., Pan, H., Wang, X., Liu, J., Su, B., Yang, C., Xu, Y., & Liu, T. (2023). Activation of Platelet mTORC2/Akt Pathway by Anti-β2GP1 Antibody Promotes Thrombosis in Antiphospholipid Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 43(10), 1818-1832. https://doi.org/10.1161/atvbaha.123.318978
Vancouver
Tang Z, Shi H, Chen C, Teng J, Dai J, Ouyang X, et al. Activation of Platelet mTORC2/Akt Pathway by Anti-β2GP1 Antibody Promotes Thrombosis in Antiphospholipid Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(10):1818-1832. doi:10.1161/atvbaha.123.318978
BibTeX
@article{Tang2023,
author = {Tang, Zihan and Shi, Hui and Chen, Changming and Teng, Jialin and Dai, Jing and Ouyang, Xinxing and Liu, Honglei and Hu, Qiongyi and Cheng, Xiaobing and Ye, Junna and Su, Yutong and Sun, Yue and Pan, Haoyu and Wang, Xuefeng and Liu, Junling and Su, Bing and Yang, Chengde and Xu, Yanyan and Liu, Tingting},
title = {Activation of Platelet mTORC2/Akt Pathway by Anti-β2GP1 Antibody Promotes Thrombosis in Antiphospholipid Syndrome},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2023},
volume = {43},
number = {10},
pages = {1818--1832},
doi = {10.1161/atvbaha.123.318978}
}
EUVIMED